阿糖胞苷和多柔比星诱导的手足红斑感觉异常综合征：伏立康唑相互作用的可能作用。
Cytarabine and Doxorubicin-Induced Palmoplantar Erythrodysesthesia Syndrome: The Possible Role of Voriconazole Interaction.
作者信息
Tavakoli-Ardakani Maria, Haghighi Shirin, Shokouhi Shervin, Abtahi-Naeini Bahareh, Meidani Mohsen, Hassanpour Rezvan, Saffaei Ali
机构信息
Department of Clinical Pharmacy, School of Pharmacy and Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Hematology and Oncology, Ayatollah Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
出版信息
Eurasian J Med. 2019 Oct;51(3):313-315. doi: 10.5152/eurasianjmed.2019.18459.
Palmoplantar Erythrodysesthesia Syndrome (PPES) caused by chemotherapeutic agents is rarely life threatening and requires a reduction in dose or discontinuation of chemotherapy. The use of cytarabine and doxorubicin in the treatment of acute myeloid leukemia (AML) along with voriconazole can potentially alter the metabolism of the drugs and cause some interactions. In this study, we presented a case of AML who received cytarabine and doxorubicin as a chemotherapy regimen and voriconazole as a prophylactic anti-fungal. In this combination, voriconazole probably inhibits the P-glycoprotein pump, which leads to an increase in the cytarabine concentration. The emphasis of this report is the awareness of clinicians and pharmacotherapists about these interactions.
化疗药物引起的手足红斑感觉异常综合征（PPES）很少危及生命，需要减少化疗剂量或停止化疗。在急性髓系白血病（AML）的治疗中使用阿糖胞苷和多柔比星，同时使用伏立康唑，可能会改变药物代谢并引起一些相互作用。在本研究中，我们报告了1例接受阿糖胞苷和多柔比星化疗方案以及伏立康唑预防性抗真菌治疗的AML患者。在这种联合用药中，伏立康唑可能抑制P-糖蛋白泵，从而导致阿糖胞苷浓度升高。本报告的重点是提高临床医生和药物治疗师对这些相互作用的认识。
Zotero 插件